Isolated Distal Deep Vein Thrombosis in the Direct Oral Anticoagulant (DOAC) Era – Should Our Management Change?
Table 2.
Comparison of complication rates between DOAC and warfarin eracohorts
| |
Total Population (n=247) |
DOAC Era (n=103) |
Warfarin Era (n=144) |
p-value |
| Major bleeding on anticoagulation (ISTH-SCC Grade 3-4[17]) |
1.6% (n=4) |
1.0% (n=1) |
2.1% (n=3) |
0.50 |
| VTE progression while on anticoagulation: |
|
|
|
|
| Total |
4.0% (n=10) |
3.9% (n=4) |
4.2% (n=6) |
0.91 |
| PE |
1.2% (n=3) |
1.9% (n=2) |
0.7% (n=1) |
0.38 |
| Types of recurrent VTE post treatment cessation: |
|
|
|
|
| Total |
5.3% (n=13) |
5.8% (n=6) |
4.9% (n=7) |
0.74 |
| PE |
2.4% (n=6) |
2.9% (n=3) |
2.1% (n=3) |
0.67 |
| DVT |
2.8% (n=7) |
2.9% (n=3) |
2.8% (n=4) |
0.95 |
| Subsequent Malignancy |
0.8% (n=2) |
1.0% (n=1) |
0.7% (n=1) |
0.81 |
| All-cause mortality |
3.2% (n=8) |
1.9% (n=2) |
4.2% (n=6) |
0.33 |
|
|
